SCHEMBL6487647

SCHEMBL6487647

N#Cc1c(NC(=O)c2ccc3c(c2)OCO3)nc2ccccc2c1NCc1cccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
CYP2D6 P10635 6/20 0.54
LMNA P02545 5/20 0.54
MAPK1 P28482 5/20 0.54
CYP3A4 P08684 5/20 0.54
CYP2C19 P33261 5/20 0.54
ALDH1A1 P00352 4/20 0.54
CLK4 Q9HAZ1 4/20 0.54
HSD17B10 Q99714 4/20 0.54
CYP1A2 P05177 4/20 0.54
USP2 O75604 3/20 0.54
CYP2C9 P11712 3/20 0.54
ALOX15 P16050 2/20 0.54
SMN1; SMN2 Q16637 5/20 0.50
KDM4E B2RXH2 4/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 3/20 0.46
RAB9A P51151 7/20 0.46
NPC1 O15118 6/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479836 0.89 ALDH1A1 (0.54) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL940779 0.88 MAPK1 (0.45) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL943391 0.87 MAPK1 (0.43) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL5231022 0.86 RAB9A (0.43) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL6488993 0.86 ALDH1A1 (0.51) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL6480107 0.84 ADORA3 (0.46) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL5224949 0.83 ADORA3 (0.48) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL6487640 0.79 ALDH1A1 (0.45) MEN1KMT2ALMNAMAPK1ALDH1A1
SCHEMBL940614 0.78 ALDH1A1 (0.44) MEN1KMT2ACYP2D6LMNAMAPK1
SCHEMBL940193 0.78 RAB9A (0.44) MEN1KMT2ACYP2D6LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP claimed
US-6969723-B2 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI - AVENTIS (FR) 2005-11-29 US claimed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US claimed
EP-1390349-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2004-02-25 EP claimed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO claimed
WO-2002096879-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-SYNTHELABO (FR) 2002-12-05 WO claimed
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP disclosed
US-6969723-B2 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI - AVENTIS (FR) 2005-11-29 US disclosed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US disclosed
EP-1390349-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2004-02-25 EP disclosed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO disclosed
WO-2002096879-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-SYNTHELABO (FR) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands ADORA3, ADORA1, ADORA2A MEN1 3078/4885KMT2A 2739/4885CYP2D6 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.